249 related articles for article (PubMed ID: 32146104)
21. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig H; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Chaturvedi S; Ataman O; Enny C; Feng H; van de Velde H; Viterbo L
Br J Haematol; 2015 Nov; 171(3):344-54. PubMed ID: 26153365
[TBL] [Abstract][Full Text] [Related]
22. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.
Li X; Huang B; Liu J; Chen M; Gu J; Li J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):913-919. PubMed ID: 33966111
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
Kastritis E; Wechalekar AD; Dimopoulos MA; Merlini G; Hawkins PN; Perfetti V; Gillmore JD; Palladini G
J Clin Oncol; 2010 Feb; 28(6):1031-7. PubMed ID: 20085941
[TBL] [Abstract][Full Text] [Related]
25. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
26. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
Chan H; Chai K; Shih S; Lewsey R; Chen K; McDiarmid B; Jackson S; Simpson D
Br J Haematol; 2019 Nov; 187(4):470-477. PubMed ID: 31298750
[TBL] [Abstract][Full Text] [Related]
27. [Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma].
Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Rinsho Ketsueki; 2015 Aug; 56(8):1069-75. PubMed ID: 26345569
[TBL] [Abstract][Full Text] [Related]
28. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Chakraborty R; Muchtar E; Kumar S; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2017 Jan; 52(1):34-40. PubMed ID: 27548464
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center.
Jimenez-Zepeda VH; Lee H; Fine N; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Indian J Hematol Blood Transfus; 2021 Oct; 37(4):675-678. PubMed ID: 34744351
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Palladini G; Paiva B; Wechalekar A; Massa M; Milani P; Lasa M; Ravichandran S; Krsnik I; Basset M; Burgos L; Nuvolone M; Lecumberri R; Foli A; Puig N; Sesta MA; Bozzola M; Cascino P; Nevone A; Ripepi J; Berti P; Casarini S; Annibali O; Orfao A; San-Miguel J; Merlini G
Blood Cancer J; 2021 Feb; 11(2):34. PubMed ID: 33594045
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
[TBL] [Abstract][Full Text] [Related]
34. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S; Muchtar E; Sidiqi MH; Jevremovic D; Dispenzieri A; Gonsalves W; Buadi F; Lacy MQ; Hayman SR; Kourelis T; Kapoor P; Go RS; Warsame R; Leung N; Rajkumar SV; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2020 May; 95(5):497-502. PubMed ID: 32010993
[TBL] [Abstract][Full Text] [Related]
35. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
36. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
37. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
[TBL] [Abstract][Full Text] [Related]
38. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
Swan D; Henderson R; McEllistrim C; Naicker SD; Quinn J; Cahill MR; Mykytiv V; Lenihan E; Mulvaney E; Nolan M; Parker I; Natoni A; Lynch K; Ryan AE; Szegezdi E; Krawczyk J; Murphy P; O'Dwyer M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):847-852. PubMed ID: 35985959
[TBL] [Abstract][Full Text] [Related]
39. CyBorD induction therapy in clinical practice.
Areethamsirikul N; Masih-Khan E; Chu CM; Jimenez-Zepeda V; Reece DE; Trudel S; Kukreti V; Tiedemann R; Chen C
Bone Marrow Transplant; 2015 Mar; 50(3):375-9. PubMed ID: 25599165
[TBL] [Abstract][Full Text] [Related]
40. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Palladini G; Sachchithanantham S; Milani P; Gillmore J; Foli A; Lachmann H; Basset M; Hawkins P; Merlini G; Wechalekar AD
Blood; 2015 Jul; 126(5):612-5. PubMed ID: 25987656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
